<DOC>
	<DOCNO>NCT00758225</DOCNO>
	<brief_summary>The scientific aim present extension study monitor long-term safety tolerability idebenone patient DMD . Furthermore , long-term effect respiratory , cardiac motor function , skeletal muscle strength/function assess .</brief_summary>
	<brief_title>Long-term Safety , Tolerability Efficacy Idebenone Duchenne Muscular Dystrophy ( DELPHI Extension )</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Completion study SNTII001 Body weight â‰¥ 25 kg Glucocorticosteroids ACEinhibitors allow , stable dosage within 2 month prior inclusion Eligibility participate present extension study confirm investigator Safety tolerability issue arise course SNTII001 opinion investigator preclude treatment idebenone Clinically significant abnormality haematology biochemistry Abuse drug alcohol Use coenzyme Q10 idebenone within 30 day prior inclusion Intake investigational drug within 30 day prior inclusion Symptomatic heart failure Previous history ventricular arrhythmia ( isolated ventricular extrasystole ) ; ventricular arrhythmia present baseline Known individual hypersensitivity idebenone excipients</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>Duchenne</keyword>
	<keyword>Idebenone</keyword>
</DOC>